Menu

Recent Interviews

Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


John Jeffrey, CEO, Saturn Oil & Gas Inc.

John Jeffrey
CEO | Saturn Oil & Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary, AB (CAN)

jjeffrey@saturnoil.com

+1-587-392-7900

Saturn Oil & Gas CEO John Jeffrey on the future of the company and ESG


05. May 2020 | 08:33 CET

Evotec, Medigene, Memphasys - the right investment timing

  • Medical
Photo credits: pixabay.com

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Society in change

Memphasys from Australia has focused on the topic of artificial insemination for several years. The market is growing because more and more couples are putting their professional career first and want to create an economic framework before completing the overall picture of a family with offspring.

However, the probability of a successful pregnancy decreases for both men and women with increasing age. Therefore, more and more couples consult medical experts to have fertilization monitored.

Market launch already in 2020

The Memphasys approach is based on the biological separation of high-quality sperm from the man's seminal fluid in order to subsequently increase the chances of success of artificial insemination. The device called FELIX carries out the separation in a few minutes, which means that the overall effort of the treatment is reduced and comfort is increased.

The product is to be launched in various countries as early as the second half of 2020. The company's market capitalisation on its home stock exchange in Australia was most recently AUD 45.34 million at AUD 0.06. The shares of Memphasys are also traded in Frankfurt.

In search of antibodies

The share price of Evotec, based in Hamburg, has been able to recover in recent weeks and was last traded at the same level as before the spread of COVID-19. Before the corona pandemic, the share price peaked at over EUR 26.00 and then dropped to a low of below EUR 19.00.

At the current level of EUR 22.30, Evotec is valued at EUR 3.36 billion. The company is engaged in the search for corona antibodies and in this context, there is a chance for investors to profit from the current situation.

Waiting for the breakthrough

Investors are currently having little luck with the shares of Medigene from Martinsried, near Munich. In the past 12 months, the share price has more than halved from over EUR 8.80 to EUR 4.16. Following the outbreak of the corona pandemic, the value of the shares even dropped to below EUR 3.40.

The market capitalisation of Medigene currently totals EUR 106.33 million. The successful development of immune therapies for the treatment of cancer will remain the company's value driver in the future. Patience is required.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. December 2020 | 14:16 CET | by Nico Popp

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

  • Medical

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

Read

24. April 2020 | 07:36 CET | by Mario Hose

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

Read

04. March 2020 | 07:27 CET | by Mario Hose

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read